Enanta Pharmaceuticals Inc (ENTA) support and resistance · rev $65.3M
Enanta Pharmaceuticals Inc (ENTA) is a biotechnology company listed on US.
This page maps Enanta Pharmaceuticals Inc (ENTA) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ENTA revenue for 2025-09-30 was $65.3M. Net income was -$81.9M. Revenue was down 3.4% from 2024-09-30 to 2025-09-30. ENTA currently screens at market cap $328.0M.
ENTA currently screens at market cap $328.0M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ENTA 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ENTA quote page for the session range and the stock page for the full model.
Not investment advice.